Frankfurt - Delayed Quote EUR

Clínica Baviera, S.A. (D9Z.F)

Compare
27.60 -0.80 (-2.82%)
As of 8:23 AM GMT+2. Market Open.
Loading Chart for D9Z.F
DELL
  • Previous Close 28.40
  • Open 27.60
  • Bid 28.00 x 33100
  • Ask 28.50 x 32100
  • Day's Range 27.60 - 27.60
  • 52 Week Range 17.20 - 29.40
  • Volume 1
  • Avg. Volume 38
  • Market Cap (intraday) 449.714M
  • Beta (5Y Monthly) 0.61
  • PE Ratio (TTM) 12.21
  • EPS (TTM) 2.26
  • Earnings Date Jul 24, 2024 - Jul 29, 2024
  • Forward Dividend & Yield 1.30 (4.51%)
  • Ex-Dividend Date May 31, 2023
  • 1y Target Est --

Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, and vías lagrimales treatments. The company is based in Madrid, Spain.

www.clinicabaviera.com

1,254

Full Time Employees

December 31

Fiscal Year Ends

Recent News: D9Z.F

Performance Overview: D9Z.F

Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

D9Z.F
21.05%
IBEX 35...
8.49%

1-Year Return

D9Z.F
55.93%
IBEX 35...
15.42%

3-Year Return

D9Z.F
114.54%
IBEX 35...
19.10%

5-Year Return

D9Z.F
134.35%
IBEX 35...
19.20%

Compare To: D9Z.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: D9Z.F

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    452.97M

  • Enterprise Value

    439.07M

  • Trailing P/E

    12.57

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.00

  • Price/Book (mrq)

    4.49

  • Enterprise Value/Revenue

    1.89

  • Enterprise Value/EBITDA

    6.37

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.84%

  • Return on Assets (ttm)

    19.03%

  • Return on Equity (ttm)

    45.73%

  • Revenue (ttm)

    227.07M

  • Net Income Avi to Common (ttm)

    35.97M

  • Diluted EPS (ttm)

    2.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    49.77M

  • Total Debt/Equity (mrq)

    51.23%

  • Levered Free Cash Flow (ttm)

    26.81M

Research Analysis: D9Z.F

Company Insights: D9Z.F

Research Reports: D9Z.F

People Also Watch